Indication

Relapsing form of multiple sclerosis

Relapsing forms of multiple sclerosis represent a category of chronic autoimmune disorders affecting the central nervous system, predominantly diagnosed in young to middle-aged adults with a female predominance. Read more about Relapsing form of multiple sclerosis

125 drugs 54 manufacturers

Advertisement

Drugs that treat it

Common Relapsing form of multiple sclerosis therapies.

Showing 1–9 of 125 drugs

KESIMPTA PEN (ofatumumab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
Novartis Pharmaceuticals

GILENYA (fingolimod HCl)

MULTIPLE SCLEROSIS AGENTS, GENERAL·RELAPSING FORM OF MULTIPLE SCLEROSIS·+1
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Relapsing form of multiple sclerosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Relapsing form of multiple sclerosis.

Relapsing forms of multiple sclerosis represent a category of chronic autoimmune disorders affecting the central nervous system, predominantly diagnosed in young to middle-aged adults with a female predominance.

In regulatory and clinical contexts, this indication encompasses clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.

Pathophysiologically, it is driven by intermittent inflammatory attacks that cause demyelination, axonal injury, and gliosis within the brain, optic nerves, and spinal cord.

Clinically, it is characterized by acute episodes of worsening neurological dysfunction, known as relapses or exacerbations, followed by periods of partial or complete symptom recovery without intervening progression.

Personalize your experience

Follow Relapsing form of multiple sclerosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it